FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

pe Response	s)																	
1. Name and Address of Reporting Person * Jones Jason C				2. Issuer Name and Ticker or Trading Symbol EKSO BIONICS HOLDINGS, INC. [EKSO]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X Officer (give title below) Other (specify below) VP of Product Development						
(Last) (First) (Middle) C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201				3. Date of Earliest Transaction (Month/Day/Year) 04/07/2022														
(Street) RICHMOND, CA 94804				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person						
<i>'</i>)	(State)		(Zip)			Ta	ble I	- Non	-Deri	vative S	ecurities	s Acqı	ıired, Di	spos	sed of, or E	Beneficially (Owned	
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)		any			f Code (Instr. 8)				of (D)	Beneficia Reported		ally Owned Following Transaction(s)		Ownership Form:	Beneficial	
				(Monui/Day/		r ear)		ode	V	Amour	(A) or (D)	Price		s an	iu 4)		or Indirect	Ownership (Instr. 4)
Stock (1)		04/07	7/2022 ⁽²⁾				1	A		50,000 (3)	A	\$ 0	131,6	37			D	
			Table II - D	Derivat	ive Sec	uriti	les Ac	quire	Personta conta the fo	ons whained in	o respo this fo plays a of, or Be	rm ar curre	e not reently va	qui lid (ired to res	pond unles	ss	1474 (9-02)
l ₂	2 Transpartion	2		~ -				ts, opt						-1	9 Dring of	0 Number o	f 10	11. Nati
		Year) E	Execution Date	e, if Transaction Code		ion	Number of		and Expiration Date (Month/Day/Year)			Am Und Sec	Amount of Underlying Securities (Instr. 3 and 4)			Derivative Securities Beneficially Owned Following Reported	Owners Form of Derivati Security Direct (or Indirects)	hip of Indir Benefic Owners (Instr. 4
											Expiratio Date	on Tit	or					
	and Address of Son C Son C Son BIONIO 14 HARBO 201 DND, CA 9 Security Report on a s Conversion or Exercise Price of Derivative	Address of Reporting Person C SO BIONICS HOLDIN 14 HARBOUR WAY 201 (Street) OND, CA 94804 (State) Gecurity Report on a separate line for Exercise Price of Derivative Son C (First) (Strest) (Street) A Stock (1) 2. Conversion or Exercise Price of Derivative	and Address of Reporting Person* Son C So BIONICS HOLDINGS, 14 HARBOUR WAY SOUT 201 (Street) DND, CA 94804 (State) Security 2. Transaction Date (Month Conversion or Exercise Price of Derivative (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year)	Address of Reporting Person* Son C (First) (Middle) SO BIONICS HOLDINGS, 14 HARBOUR WAY SOUTH, 201 (Street) OND, CA 94804 (State) (Zip) Security 2. Transaction Date (Month/Day/Year) Table II - E (Conversion or Exercise Price of Derivative) 1. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) (Month/Day/Year)	and Address of Reporting Person* 2. Iss Son C Son C (First) (Middle) 3. Date (04/07) 4. If A DND, CA 94804 (Street) 2. Transaction Date (Month/Day/Year) A Stock (1) Report on a separate line for each class of securities berefit (e.g., pu Conversion or Exercise Price of Derivative Table II - Derivative (Month/Day/Year) A Stock (1) A Stock (1)	2. Issuer Na EKSO BIC 3. Date of Ear 04/07/2022 (Street) 4. If Amendm OND, CA 94804 (State) 2. Transaction Date (Month/Day/Year) A Stock (1) Conversion or Exercise Price of Derivative a Stock (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 4. If Amendm 2. Transaction Date (E.g., puts, call) 4. Transaction Date (Month/Day/Year) A Stock (II) A Stock (III) A Stock (IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	2. Issuer Name a EKSO BIONIC SON C (First) (Middle) SO BIONICS HOLDINGS, 14 HARBOUR WAY SOUTH, 201 (Street) 4. If Amendment, 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Table II - Derivative Security (e.g., puts, calls, was 2. Conversion or Exercise Price of Derivative Security (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 3. Transaction Code (Instr. 8)	2. Issuer Name and Ti EKSO BIONICS H SO BIONICS HOLDINGS, 14 HARBOUR WAY SOUTH, 201 (Street) 2. Transaction Date (Month/Day/Year) A Stock (1) A Stock (1) A Stock (1) A Stock (1) Conversion or Exercise Price of Derivative Security A Table II - Derivative Securities Ac (e.g., puts, calls, warrant any (Month/Day/Year) (Month/Day/Year) A Demed Execution Date, if Cod (Insum (Month/Day/Year)) Table II - Derivative Securities Ac (e.g., puts, calls, warrant any (Month/Day/Year) A Demed Execution Date, if Transaction any (Month/Day/Year) A Demed Execution Date, if Transaction Code of Derivative Security (Month/Day/Year) A Demed Execution Date, if Transaction any (Month/Day/Year) (Month/Day/Year) A Demed Execution Date, if Transaction Code of Derivative Security (Month/Day/Year) A Demed Execution Date, if Transaction Code of Derivative Security (Month/Day/Year) A Demed Execution Date, if Transaction Code of Derivative Security A Demiv Execution Date, if Transaction Code of Derivative Security A Demiv Execution Date, if Transaction Code of Derivative Security A Demiv Execution Date, if Transaction Code of Derivative Security A Demiv Execution Date, if Transaction Code of Derivative Security A Demiv Execution Date, if Transaction Code of Derivative Security A Demiv Execution Date, if Transaction Code of Derivative Security A Demiv Execution Date, if Transaction Code of Derivative Security A Demiv Execution Date, if Transaction Code of Derivative Security A Demiv Execution Date of Derivative Securities Demiv Execution Date of Derivative Security A Demiv Execution Date of Derivative Securities Demiv Execution Date of Derivative Security A Demiv Execution Date of Derivative Securities Demiv Execution Date of Derivative Securities Demiv Execution Date of Derivative Security A Demiv Execution Date of Derivative Securities Demiv Execution Date of Derivative Security A Demiv Execution Date of Derivative Securities Demiv Execution Date of Derivative Security A Demiv Execution Date of Derivative S	2. Issuer Name and Ticker of EKSO BIONICS HOLD 3. Date of Earliest Transaction 04/07/2022 3. Date of Earliest Transaction 04/07/2022 4. If Amendment, Date Origin Onto, CA 94804 5. Table I - Non October 1	2. Issuer Name and Ticker or Trac EKSO BIONICS HOLDINGS 3. Date of Earliest Transaction (Mo 04/07/2022 4. If Amendment, Date Original Fil DND, CA 94804 2. Transaction Date (Month/Day/Year) A Stock (I) O4/07/2022(2) A Report on a separate line for each class of securities beneficially owned directly or in or Exercise or Exercise (Month/Day/Year) Table II - Derivative Securities Acquired, Dis (e.g., puts, calls, warrants, options, any (Month/Day/Year) A Stock (II) Table II - Derivative Securities Acquired, Dis (e.g., puts, calls, warrants, options, any (Month/Day/Year) (Month/Day/Year) A Date Table II - Derivative Securities Acquired, Dis (e.g., puts, calls, warrants, options, and Execution Date, if Original File (Month/Day/Year) Persocontative Securities Acquired, Dis (e.g., puts, calls, warrants, options, and Execution Date, if Original File (Month/Day/Year) Date Table II - Derivative Securities Acquired, Dis (e.g., puts, calls, warrants, options, and Execution Date, if Original File (Month/Day/Year) Date Date Date	2. Issuer Name and Ticker or Trading Syr EKSO BIONICS HOLDINGS, INC (Middle) 3. Date of Earliest Transaction (Month/Day 04/07/2022) (Street) 4. If Amendment, Date Original Filed(Month Day O4/07/2022) (State) (Zip) Table I - Non-Derivative Securities Deneficially owned directly or indirectly any (Month/Day/Year) (Stock (I) 04/07/2022(2) A 50,000 (3) Report on a separate line for each class of securities beneficially owned directly or indirectly any (Month/Day/Year) 2. Table II - Derivative Securities Acquired, Disposed of Code (Instr. 3) Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Instr. 3) A Deemed Execution Date, if Code (Instr. 8) Persons who contained in the form dis any (Month/Day/Year) (Month/Day/Year) (Instr. 8) Date Execution Date, if Code (Instr. 8) Persons who contained in the form dis Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) Date Date	2. Issuer Name and Ticker or Trading Symbol EKSO BIONICS HOLDINGS, INC. [EKSO BIONICS HOLDINGS, INC. IEKSO BIONICS HOLDING, INC. IEKSO BIONICS HOLDINGS, INC. IEKSO BIONICS HOLDING, INC. I	2. Issuer Name and Ticker or Trading Symbol EKSO BIONICS HOLDINGS, INC. [EKSO] 3. Date of Earliest Transaction (Month/Day/Year) 4. If Amendment, Date Original Filed(Month/Day/Year) 5. DND, CA 94804 5. DND, CA 94804 6. Security 2. Transaction Date (Month/Day/Year) 6. Security 2. Transaction Date (Month/Day/Year) 6. Stock (I) 04/07/2022 2. A Deemed Execution Date, any (Month/Day/Year) 6. Code (Instr. 8) 6. Ode (A) or Disposed of (D) (Instr. 8) 6. Oate Exercise Code (A) or Beneficially owned directly or indirectly. 2. Table II - Derivative Securities Acquired, Disposed of, or Beneficial Security 6. Security 7. Table II - Derivative Securities Acquired, Disposed of, or Beneficial Securities Acquired (A) or Disposed of (D) (Instr. 8) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 8) 7. Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 8) 7. Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 8) 7. Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 8. Date Expiration Table II - Date Expiration Table II	2. Issuer Name and Ticker or Trading Symbol EKSO BIONICS HOLDINGS, INC. [EKSO] 5. Relation C 6. (First) (Middle) (Midd	2. Issuer Name and Ticker or Trading Symbol EKSO BIONICS HOLDINGS, INC. [EKSO] SO BIONICS HOLDINGS, 14 HARBOUR WAY SOUTH, 201 (Street) OND, CA 94804 2. Transaction Date (Month/Day/Year) (State) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 4. If Amendment, Date Original Filed, Month/Day/Year) (Instr. 3, 4 and 5) 2. Transaction Date (Instr. 8) (Instr. 3, 4 and 5) 2. Transaction Date (A) or Disposed of (D) (Instr. 3) (Instr. 3, 4 and 5) 3. Transaction (Instr. 3) (A) (A) (B) Persons who respond to the collect contained in this form are not required for many (Month/Day/Year) (Instr. 3) (Inst	2. Issuer Name and Ticker or Trading Symbol EKSO BIONICS HOLDINGS, INC. [EKSO] 3. Date of Earliest Transaction (Month/Day/Year) 04/07/2022 4. If Amendment, Date Original Filed(Month/Day/Year) 0ND, CA 94804 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 4. If Amendment, Date Original Filed(Month/Day/Year) 2. Transaction Date (Month/Day/Year) 4. Stock (Instr. 8) 1. Stock (Instr. 3, 4 and 5) 2. Transaction Code (Instr. 3) Date 2. Transaction (Instr. 3) Date Date (Month/Day/Year) 3. Transaction (Instr. 3) Date Date (Month/Day/Year) 4. Stock (Instr. 3) Date Date (Month/Day/Year) 3. Transaction (Instr. 3) Date Date (Month/Day/Year) 4. Stock (Instr. 3) Date Date (Month/Day/Year) 3. Transaction (Instr. 3) Date Date Derivative Securities Acquired (Month/Day/Year) Date Date Execution Date, if Code (Month/Day/Year) Date Date Date Execution Date, if Code (Month/Day/Year) Date Execution Da	2. Issuer Name and Ticker or Trading Symbol EKSO BIONICS HOLDINGS, INC. [EKSO] 5. Relationship of Reporting Person (Check all applies Director (Check all applies Directo	2. Issuer Name and Ticker or Trading Symbol EKSO BIONICS HOLDINGS, INC. [EKSO] Of (First) (Middle) Odd (Middl

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Jones Jason C C/O EKSO BIONICS HOLDINGS, INC. 1414 HARBOUR WAY SOUTH, SUITE 1201 RICHMOND, CA 94804			VP of Product Development					

Signatures

/s/ Jerome Wong, as attorney-in-fact	04/11/2022
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents restricted stock units ("RSUs").
- (2) The grant of RSUs was approved by the Compensation Committee of the Board of Directors on April 7, 2022.
- (3) 1/3 of the total number of shares of Common Stock subject to the RSUs shall vest on August 30th of each year beginning 2022.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Know all by these presents, that the undersigned hereby constitutes and appoints each of Jack Peurach, Jack Glenn and Jerome Wong of Ekso Bionics Holdings, Inc. (the "Company"), or either of them signing singly, and with the full power of substitution, the undersigned's true and lawful attorney- in-fact to:

- 1. Prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") Forms 3, 4 and 5 (including amendments thereto and joint filing agreements in connection therewith, and any other documents necessary or appropriate to enable the undersigned to make electronic filings with the SEC of reports required by) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or any rule or regulation of the SEC in the undersigned's capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of the Company;
- 2. Prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the SEC Schedule 13D or Schedule 13G (including amendments thereto and joint filing agreements in connection therewith) in accordance with Sections 13(d) and 13(g) of the Exchange Act and the rules thereunder in the undersigned's capacity as beneficial owner of more than 5% of a registered class of securities of the Company;
- 3. Do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any of such Forms 3, 4 or 5 and Schedules 13D or 13G (including amendments thereto and joint filing agreements in connection therewith) and timely file such forms or schedules with the SEC and any stock exchange, self-regulatory association or any similar authority; and
- 4. Take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact in serving in such capacity at the request of the undersigned, are not assuming (nor is the Company assuming) any of the undersigned's responsibilities to comply with Sections 13 or 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 or Schedules 13D or 13G with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact is no longer employed by the Company or Morrison & Foerster LLP, as applicable.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date written below.

Date: August 3, 2021

/s/ Jason C. Jones Name: Jason C. Jones

Title: VP of Product Development